Chimerix Seeks FDA Approval for New Drug Targeting Deadly Brain Cancer
Chimerix Seeks FDA Approval for New Drug Targeting Deadly Brain Cancer
Chimerix尋求FDA批准新藥以治療致命的腦癌
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today confirms that the Company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma in the United States.
Chimerix（納斯達克：CMRX）是一家生物製藥公司，致力於開發能夠顯著改善和延長面臨致命疾病的患者生命的藥物。今天確認，公司已向美國食品和藥物管理局（FDA）提交了一份新藥申請（NDA），尋求對dordaviprone的加速批准，以治療美國H3 K2700萬突變瀰漫性膠質瘤復發患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。